arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

IDEAYA Biosciences, Inc.

IDYA
$37.02 ▲ +0.80 (+2.19%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

IDEAYA Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.3B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -9.1%
FCF / Share $-0.86
Trailing P/E
Price / Book 3.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.56M
↓ -39.7%
Net Income Profit after all expenses
$-98.54M
↓ -36.5%
Operating Margin Operating profit as % of sales
52.2%
↑ +112.5% 3th
FCF / Share Free cash flow per share
$-0.86
↓ -23.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
33
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters